{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=5", "query": { "intervention": "enfortumab vedotin", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T14:58:30.447Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05614739", "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms", "Neoplasm Metastasis", "Ureteral Neoplasms" ], "interventions": [ { "name": "Vepugratinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 677, "start_date": "2023-01-12", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 41, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614739" }, { "nct_id": "NCT06891560", "title": "A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "Enfortumab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-03-31", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "East White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891560" }, { "nct_id": "NCT06553885", "title": "Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Enfortumab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-04-01", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06553885" }, { "nct_id": "NCT06470282", "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Muscle-Invasive Bladder Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" }, { "name": "Cystoscopy (CS)", "type": "PROCEDURE" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-03-31", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06470282" }, { "nct_id": "NCT07087860", "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma", "Refractory Bladder Urothelial Carcinoma", "Refractory Renal Pelvis and Ureter Urothelial Carcinoma", "Stage IV Bladder Cancer AJCC v7", "Stage IV Renal Pelvis and Ureter Cancer AJCC v7" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Central Venous Cannula Insertion", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plasmapheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Antibody-Drug Conjugate Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-08-01", "completion_date": "2028-08-07", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07087860" }, { "nct_id": "NCT04754191", "title": "Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 34, "start_date": "2022-06-05", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04754191" }, { "nct_id": "NCT05845814", "title": "A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Urothelial Neoplasms" ], "interventions": [ { "name": "Coformulated favezelimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Coformulated vibostolimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "EV", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2023-06-23", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 14, "location_summary": "La Jolla, California • Orange, California • San Francisco, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05845814" }, { "nct_id": "NCT02091999", "title": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Cancer and Other Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2014-05-14", "completion_date": "2022-12-07", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 18, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091999" }, { "nct_id": "NCT04223856", "title": "Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 886, "start_date": "2020-03-30", "completion_date": "2028-03-01", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Burbank, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04223856" }, { "nct_id": "NCT07484022", "title": "Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Urothelial Cancer", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "GB-4362", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Generate Biomedicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-06-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T14:58:30.447Z", "location_count": 10, "location_summary": "Duarte, California • Irvine, California • Orlando, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tucker", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07484022" } ] }